The company presented the findings at ACG 2018, Oct. 5-10 in Philadelphia.
Here’s what you should know:
1. Researchers conducted four phase 3 trials. They tested Trulance in adults more than 65 years old with CIC and IBS-C.
2. Trulance was both safe and tolerable in patients aged 65 years old and older, with results comparable to a younger cohort.
3. Adverse events were similar between the two cohorts.
4. Synergy also conducted two studies testing Synergy in CIC patients receiving concomitant acid suppression therapy. In this study, 883 patients received Trulance and 892 received a placebo. Ten percent of the combined cohorts were receiving acid suppression therapy. Efficacy and safety results were similar to the overall population.
5. Synergy CMO Patrick Griffin, MD, said, “We are excited to provide healthcare professionals with new evidence to further reinforce Trulance as an efficacious treatment option with a strong safety profile for patients aged 65 years and older, as well as for patients who require concomitant acid suppression therapy.”
More articles on gastroenterology:
Drs. Steven Matulis, Douglas Morgan, & more: 6 GI physicians making headlines
North Carolina finalizes plan that could spur ASC, hospital developments — 5 takeaways
Vizinet awards 5 Ambulatory Care Quality and Accountability awards — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.